{"id":3297,"date":"2006-05-12T08:44:21","date_gmt":"2006-05-12T07:44:21","guid":{"rendered":"http:\/\/moomango.co.uk\/htb\/?p=3297"},"modified":"2013-12-06T18:44:41","modified_gmt":"2013-12-06T18:44:41","slug":"development-of-d-d4fc-dexelvucitabine-reverset-discontinued","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/3297","title":{"rendered":"Development of d-d4FC (dexelvucitabine, Reverset) discontinued"},"content":{"rendered":"<p><strong>Simon Collins, HIV i-Base<\/strong><\/p>\n<p><strong>On 3 April, Incyte announced that it was discontinuing development of the nucleoside analogue d-d4FC (formerly Reverset). This is due to 40% incidence of grade 4 hyperlipasemia (a marker of pancreatic inflammation) including one case of pancreatitis, in patients receiving 200 mg d-d4FC without 3TC or FTC in their combination.<\/strong><\/p>\n<p>Although hyperlipasemia was only reported in 2% in people using 3TC or FTC, early virological results showed that d-d4FC was significantly less potent if used in regimens that included either of these drugs &#8211; in itself a significant limitation for any nucleoside. The toxicity reported without 3TC or FTC makes it impossible to see any context in which to use d-d4FC.<\/p>\n<p>The increased incidence of grade 4 hyperlipasemia was observed in Study 901, the long-term extension of Incyte\u0092s first Phase IIb trial (Study 203).<\/p>\n<p>Source: Incyte Press Release<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Simon Collins, HIV i-Base On 3 April, Incyte announced that it was discontinuing development of the nucleoside analogue d-d4FC (formerly Reverset). This is due to 40% incidence of grade 4 hyperlipasemia (a marker of pancreatic inflammation) including one case of &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-3297","post","type-post","status-publish","format-standard","hentry","category-antiretrovirals"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/3297","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=3297"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/3297\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=3297"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=3297"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=3297"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}